Basic & Clinical Medicine ›› 2017, Vol. 37 ›› Issue (11): 1585-1589.

Previous Articles     Next Articles

Rosiglitazone alleviates vascular endothelial dysfunction in type 2 diabetic rats

  

  • Received:2016-10-20 Revised:2016-12-29 Online:2017-11-05 Published:2017-11-01
  • Contact: liye Hu E-mail:qianqianhu1998@163.com
  • Supported by:
    Early detection and drug intervention study of subclinical vascular lesions in different glucose tolerance crowd

Abstract: Objective To observe metabolic abnormalities, histology changes and eNOS expression of aorta in type 2 diabetes rat. And to observe intervention effect of rosiglitazone. Methods 80 male Wistar rats were randomized to control group, high diet group, diabetes group, and rosiglitazone treatment group (diabetes plus rosiglitazone treatment). Type 2 diabetes models were developed and rosiglization group was treated with rosiglitazone. After 6 weeks and 12 weeks of treatment with rosiglitazone, blood glucose, endothlin and nitric oxide were tested. Histology changes of aorta in different groups were observed under the light microscope. Meanwhile, study the protein and mRNA expression of eNOS in aorta. Results 1) Compared with control group, ET in high fat diet group, diabetes group and rosiglitazone group increased significantly, and the level of NO decreased significantly at 6 week and 12 week. At 12 week, ET in diabetes group increased, and NO decreased significantly than that of high fat diet group and rosiglitazone group. 2) Different degree of histology changes were observed in high fat diet group, diabetes group and rosiglitazone group at 12 week. 3) Compared with control group, protein and mRNA expression in high fat diet group, diabetes group and rosiglitazone group were down regulated at 6 week and 12 week. And protein expression in diabetes group was down regulated than that in rosiglitazone group. Conclusion Rosiglization can ease the endothelial dysfunction in type 2 diabetes rat.

Key words: diabete rat, nitric oxide, endothelia nitric oxide synthase, aorta, rosiglitazone